The Venture Codex

Participated · Series A · Jul 2026

Mochi Intelligence is an embodied intelligence startup founded by veterans from Huawei and logistics operations, building service-oriented robots with a long-term vision of general-purpose household robots. The company has kept product specifications private so far and has not disclosed customers, orders, delivery volumes, or revenue. Leadership includes Huang Qingqiu, formerly head of Huawei's Autonomous Driving AI division, and CEO Gao Wenli, who has experience in Huawei's carrier business and co-founded iMile; investors cited their track records as a key rationale for the company's valuation. Mochi plans to launch its first service-oriented robot in July and will initially target commercial service scenarios where environments are more static and tasks more defined. The company intends to use real-world deployments to collect data and iterate its algorithms, mirroring closed-loop training approaches used in autonomous driving, before expanding toward household applications.

Participated · Equity · Jul 2026

Moqi develops real-time embodied systems that integrate hardware, software, algorithms and data for robotic applications. The company is porting proven autonomous-driving methods — such as data loops, on-device model optimization and mass-production quality control — into embodied AI. It plans to deploy robots first in commercial service settings and later move into homes, with a long-term aim of creating a self-evolving household robot. Moqi is pre-revenue and intends to accelerate development of its embodied foundation model and data-loop infrastructure using fresh capital. The startup was founded in late 2025 and is led by CEO Gao Wenli, a co-founder of cross-border logistics firm iMile, and CTO Huang Qingqiu, who previously headed AI for Huawei’s smart-driving unit. The company’s strategy reflects a winner-takes-most approach amid a financing rush in Chinese embodied intelligence.

Participated · Series B · May 2026

Tianji Intelligence has built a full-stack R&D and mass production system spanning core sensors, integrated joints, controllers and a product matrix handling loads from 3kg to 20kg. It is the first embodied intelligence company to develop its own MEMS joint torque sensors and deploy them in robot joints and has engineered a "one-drive-two" coordination architecture to synchronize two 7-axis force-control arms from a single motherboard. Tianji's Marvin force-control humanoid dual-arm has demonstrated latency as low as 5ms and an average error of 1.89mm in recent tests. Its lightweight integrated joint module, the Marvin M6S Lite, achieves a 62.5% load-to-weight ratio, weighing 8kg while handling a 5kg payload and offering an 8kHz torque closed loop with four-loop control. In the first four months of 2025 the company delivered over 2,000 force-control humanoid dual arms to more than 100 clients, became the largest shipper globally by volume for such systems, and reported backlog orders exceeding 10,000 units in Q1. Its customer base includes 45 global humanoid robot OEMs and other embodied intelligence unicorns, and the company aims to use scale and the new funding to expand R&D, production and global sales.

Participated · Series A · Apr 2026

Axoft develops implantable brain-computer interfaces (iBCIs) built from its proprietary bio-inspired Fleuron™ material, designed to improve biocompatibility and neural data quality. Fleuron is reported to be up to 10,000x softer than polyimide, offers greater region access and higher sensor/stimulator density per thread, and reduces signal attenuation versus standard flexible probes. The company has demonstrated first-in-human implants in more than 11 patients and completed a study at The Panama Clinic with four patients undergoing tumor resection, recording cortical and subcortical activity. Axoft has research published in Nature (December 2023 and June 2025) showing scalable single-cell electrophysiology enabled by its materials and interfaces. The company has commercialized Fleuron via an exclusive licensing agreement with Stanford and secured a joint development agreement with Kayaku Advanced Materials, alongside grant funding to build a GMP manufacturing facility. Co-founded in 2021 and headquartered in Cambridge, Massachusetts, Axoft has opened a subsidiary in Grenoble, France, and plans to scale manufacturing and expand engineering, microfabrication and chemistry teams as it advances clinical programs and regulatory work.

Participated · Equity · Apr 2026

Pulnovo Medical develops a proprietary Pulmonary Artery Denervation (PADN) System, a minimally invasive therapy aimed at modulating sympathetic nerve activity implicated in pulmonary vascular remodeling and cardiopulmonary disease progression. The company reports about 1,500 PADN procedures performed globally and regulatory approvals in seven countries, and it is advancing commercialization across the European Union, Middle East, and China. Pulnovo's therapy has been referenced in multiple international clinical guidelines, including the 2022 ESC/ERS Guidelines, and clinical studies are ongoing in Europe and Asia with U.S. IDE trials recently initiated. In the United States the company has received FDA Breakthrough Device designation and has started two fully approved IDE trials, including the PULSE-LHD trial. Following the $100 million strategic financing led by Medtronic, Pulnovo plans to use proceeds to support clinical development, regulatory submissions, international commercialization, and continued technology investment. The company is also expanding its leadership team, hiring a Chief Strategy Officer to strengthen ties with global capital markets and industry partners.